Table 7 Disease-free survival of AML patients in relation to gene polymorphism of CYP2B6 and CYP3A4
n | 9 months Cumulative Survival (%) | Median Survival time (95%CI) (months) | p value | |
|---|---|---|---|---|
Whole group | 30 | 46.6 | 9.0 (5.8-12.2) | |
CYP2B6 | ||||
Wild | 12 | 63.5 | * | |
Mutant | 18 | 38.5 | 8.0 (6.0-10.0) | 0.352 |
CYP3A4 | ||||
Wild | 20 | 50.7 | * | 0.195 |
Mutant | 10 | 36.0 | 7.0 (4.3-9.7) | |
Single vs. Combined | ||||
Single Mutation | 12 | 46.9 | * | 0.265 |
Combined Mutations | 8 | 31.3 | 7.0 (4.7-9.3) | |